159 related articles for article (PubMed ID: 37148678)
1. Investigation of Macrocyclic mTOR Modulators of Rapamycin Binding Site via Pharmacoinformatics Approaches.
Parate S; Kumar V; Hong JC; Lee KW
Comput Biol Chem; 2023 Jun; 104():107875. PubMed ID: 37148678
[TBL] [Abstract][Full Text] [Related]
2. New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation.
Kist R; Caceres RA
J Biomol Struct Dyn; 2017 Dec; 35(16):3555-3568. PubMed ID: 27860549
[TBL] [Abstract][Full Text] [Related]
3. In Silico Strategy for Targeting the mTOR Kinase at Rapamycin Binding Site by Small Molecules.
Vittorio S; Gitto R; Adornato I; Russo E; De Luca L
Molecules; 2021 Feb; 26(4):. PubMed ID: 33669763
[TBL] [Abstract][Full Text] [Related]
4. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
5. Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions.
Nasr AB; Ponnala D; Sagurthi SR; Kattamuri RK; Marri VK; Gudala S; Lakkaraju C; Bandaru S; Nayarisseri A
Bioinformation; 2015; 11(6):307-15. PubMed ID: 26229292
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore-guided fragment-based design of novel mammalian target of rapamycin inhibitors: extra precision docking, fingerprint-based 2D and atom-based 3D-QSAR modelling.
Kumar A; Rai S; Rathi E; Agarwal P; Kini SG
J Biomol Struct Dyn; 2021 Mar; 39(4):1155-1173. PubMed ID: 32037974
[TBL] [Abstract][Full Text] [Related]
7. Searching for potential mTOR inhibitors: Ligand-based drug design, docking and molecular dynamics studies of rapamycin binding site.
Kist R; Timmers LFSM; Caceres RA
J Mol Graph Model; 2018 Mar; 80():251-263. PubMed ID: 29414044
[TBL] [Abstract][Full Text] [Related]
8. Identification of Multi-kinase Allosteric Inhibitors of Oncogenic Targets EGFR1, PI3K, and BRAF Kinase.
Kakarala KK; Jamil K
Curr Comput Aided Drug Des; 2022; 18(7):506-518. PubMed ID: 36321226
[TBL] [Abstract][Full Text] [Related]
9. Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).
Oleksak P; Nepovimova E; Chrienova Z; Musilek K; Patocka J; Kuca K
Eur J Med Chem; 2022 Aug; 238():114498. PubMed ID: 35688004
[TBL] [Abstract][Full Text] [Related]
10. Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics.
Parate S; Kumar V; Lee G; Rampogu S; Hong JC; Lee KW
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33801030
[TBL] [Abstract][Full Text] [Related]
11. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
12. Overview of Research into mTOR Inhibitors.
Mao B; Zhang Q; Ma L; Zhao DS; Zhao P; Yan P
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014530
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
[TBL] [Abstract][Full Text] [Related]
14. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
15. A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches.
Mohd Rehan
J Mol Graph Model; 2015 Nov; 62():226-234. PubMed ID: 26500112
[TBL] [Abstract][Full Text] [Related]
16. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
18. The role of glycerol-water mixtures in the stability of FKBP12-rapalog-FRB complexes.
Lopez JJD; Gaza JT; Nellas RB
J Mol Graph Model; 2023 Nov; 124():108556. PubMed ID: 37423019
[TBL] [Abstract][Full Text] [Related]
19. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
Lv X; Ma X; Hu Y
Expert Opin Drug Discov; 2013 Aug; 8(8):991-1012. PubMed ID: 23668243
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.
Blaser B; Waselle L; Dormond-Meuwly A; Dufour M; Roulin D; Demartines N; Dormond O
BMC Cancer; 2012 Mar; 12():86. PubMed ID: 22401294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
